By Sabela Ojea
Shares of Allurion Technologies on Friday surged a day after the company said it received positive results about the effectiveness of its gastric balloon in combination with a low dose of the weight-loss and type 2 diabetes therapy GLP-1.
The stock was up 40% to $3.20 in morning trading. Shares have, however, dropped 93% over the past 12 months.
The weight-loss technology company said that the results indicated the combination increases weight loss and the patients didn't experience as many side effects, such as muscle wasting, and had improve adherence.
Muscle wasting and lack of adherence are significant challenges for GLP-1 therapies, Allurion Chief Executive Shantanu Gaur said.
"We plan on building upon this promising initial data and are optimistic that this could become a new standard of care for patients who want metabolically healthy weight loss," Gaur said.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
March 21, 2025 11:02 ET (15:02 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.